Loading…
Reported covered position: U.S. Senator
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Medicare policies.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Source: Senate LDA
| BIOTECHNOLOGY INNOVATION ORGANIZATION |
| 7 |
| 2025–2026 |
| COALITION FOR SMARTER REGULATION OF NICOTINE | 7 | 2025–2026 |
| NOVARTIS | 7 | 2025–2026 |
| UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 7 | 2025–2026 |
| ATLANTIC COAST CONFERENCE | 6 | 2025–2026 |
| NAPATREE TECHNOLOGY, LLC | 6 | 2025–2026 |
| UNITED WAY WORLDWIDE | 6 | 2025–2026 |
| ASSOCIATION OF AMERICAN UNIVERSITIES | 5 | 2025–2026 |
| AVALYN PHARMA INC. | 5 | 2025–2026 |
| DUKE UNIVERSITY HEALTH SYSTEM | 5 | 2025 |
| LAZARUS AI | 5 | 2025 |
| REGENXBIO INC. | 5 | 2025–2026 |
| PARTICULA GROUP INC. | 4 | 2026 |
| CROWDSTRIKE, INC. | 3 | 2026 |
| HADRON ENERGY, INC. | 2 | 2026 |
| NATIONAL EMPLOYMENT OPPORTUNITIES NETWORK | 2 | 2026 |
| PIVOTAL HEALTH | 2 | 2026 |
| STAX ENGINEERING, INC. | 2 | 2026 |
| TTX COMPANY | 2 | 2026 |
| MICHAELS STORES, INC. | 1 | 2026 |
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Policy issues related to tokenized assets. H.R. 3633, Digital Asset Market Clarity Act of 2025.
Policy issues related to tokenized assets. H.R. 3633, Digital Asset Market Clarity Act of 2025.
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act. S. 4668, Protect College Sports Act.
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act. S. 4668, Protect College Sports Act.
Policies and proposals impacting higher education for health sciences. Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act.
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 8646, Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 8646, Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
National Defense Authorization Act for Fiscal Year 2027
Client: CROWDSTRIKE, INC. · Firm: DLA PIPER LLP (US)
Policies and proposals related to cybersecurity. H.R. 8800, National Defense Authorization Act, FY 2027, policies and proposals related to cybersecurity.
National Defense Authorization Act for Fiscal Year 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
National Defense Authorization Act for Fiscal Year 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. S. 4668, Protect College Sports Act.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Department of Defense Appropriations Act, 2027
Client: NAPATREE TECHNOLOGY, LLC · Firm: DLA PIPER LLP (US)
H.R. 9495/S. 4784, Department of Defense Appropriations Act for FY2027, provisions on defense technology.
Department of Defense Appropriations Act, 2027
Client: NAPATREE TECHNOLOGY, LLC · Firm: DLA PIPER LLP (US)
H.R. 9495/S. 4784, Department of Defense Appropriations Act for FY2027, provisions on defense technology.
Student Athlete Fairness and Enforcement Act
Client: ATLANTIC COAST CONFERENCE · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act. S. 4668, Protect College Sports Act.
Student Athlete Fairness and Enforcement Act
Client: ATLANTIC COAST CONFERENCE · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act.
Student Athlete Fairness and Enforcement Act
Client: ATLANTIC COAST CONFERENCE · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act. S. 4668, Protect College Sports Act.
Policies and proposals related to federal research funding. Federal student aid. S. 4668, Protect College Sports Act.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Protect College Sports Act of 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. S. 4668, Protect College Sports Act.
Protect College Sports Act of 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Protect College Sports Act of 2026
Client: ATLANTIC COAST CONFERENCE · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act. S. 4668, Protect College Sports Act.
Protect College Sports Act of 2026
Client: ATLANTIC COAST CONFERENCE · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act. S. 4668, Protect College Sports Act.
Policies and proposals related to federal research funding. Federal student aid. S. 4668, Protect College Sports Act.
National Defense Authorization Act for Fiscal Year 2027
Client: NAPATREE TECHNOLOGY, LLC · Firm: DLA PIPER LLP (US)
H.R. 9495/S. 4784, Department of Defense Appropriations Act for FY2027, provisions on defense technology.
National Defense Authorization Act for Fiscal Year 2027
Client: NAPATREE TECHNOLOGY, LLC · Firm: DLA PIPER LLP (US)
H.R. 9495/S. 4784, Department of Defense Appropriations Act for FY2027, provisions on defense technology.
Improve and Enhance the Work Opportunity Tax Credit Act
Client: NATIONAL EMPLOYMENT OPPORTUNITIES NETWORK · Firm: DLA PIPER LLP (US)
Extension and improvements to federal employment tax credits. S. 492, Improve and Enhance the Work Opportunity Tax Credit Act.
Improve and Enhance the Work Opportunity Tax Credit Act
Client: NATIONAL EMPLOYMENT OPPORTUNITIES NETWORK · Firm: DLA PIPER LLP (US)
Extension and improvements to federal employment tax credits. S. 492, Improve and Enhance the Work Opportunity Tax Credit Act.
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision".
Client: STAX ENGINEERING, INC. · Firm: DLA PIPER LLP (US)
S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision"
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision".
Client: STAX ENGINEERING, INC. · Firm: DLA PIPER LLP (US)
S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision."
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to university endowment tax. H.R. 1, One Big Beautiful Bill Act, university endowment tax.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to university endowment tax. H.R. 1, One Big Beautiful Bill Act, university endowment tax. Federal Student Aid.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: WAKE FOREST UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 1, One Big Beautiful Bill Act, federal student aid.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: WAKE FOREST UNIVERSITY · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, university endowment tax.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: WAKE FOREST UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 1, One Big Beautiful Bill Act, federal student aid.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: WAKE FOREST UNIVERSITY · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, university endowment tax.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BIOGEN, INC. · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: ASSOCIATION OF AMERICAN UNIVERSITIES · Firm: DLA PIPER LLP (US)
Research security, research funding, and the importance of American research enterprise and higher education. H.R. 5304/S. 2587, Departments of Labor/HHS/Education Appropriations Act, FY2026, provisions on federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act of FY2026, provisions regarding the DETERRENT Act.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Department of Defense Appropriations Act, 2026
Client: NAPATREE TECHNOLOGY, LLC · Firm: DLA PIPER LLP (US)
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on defense technology.
Department of Defense Appropriations Act, 2026
Client: NAPATREE TECHNOLOGY, LLC · Firm: DLA PIPER LLP (US)
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on defense technology.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: COALITION FOR SMARTER REGULATION OF NICOTINE · Firm: DLA PIPER LLP (US)
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act.
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act.
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ASSOCIATION OF AMERICAN UNIVERSITIES · Firm: DLA PIPER LLP (US)
Research security, research funding, and the importance of American research enterprise and higher education. H.R. 5304/S. 2587, Departments of Labor/HHS/Education Appropriations Act, FY2026, provisions on federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ASSOCIATION OF AMERICAN UNIVERSITIES · Firm: DLA PIPER LLP (US)
Research security, research funding, and the importance of American research enterprise and higher education. H.R. 5304/S. 2587, Departments of Labor/HHS/Education Appropriations Act, FY2026, provisions on federal research funding.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Healthcare provisions in appropriations and budget legislation.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
HADRON ENERGY, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Advocacy for design and development funding and federal adoption of micro modular nuclear reactor technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
PIVOTAL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Independent dispute resolution under the No Surprises Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Trade-related public policy around tariffs and intellectual property.
Issues related to tax reform.
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to federal research funding. Federal student aid. S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATLANTIC COAST CONFERENCE via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act. S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STAX ENGINEERING, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TTX COMPANY via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to truck size and weight issues. Surface Transportation Board reauthorization. Polices and proposals related to the railroad industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Center for Tobacco products oversight. FDA oversight. H.R. 8646, Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
NAPATREE TECHNOLOGY, LLC via DLA PIPER LLP (US)
2026 · third_quarter · Q3
H.R. 9495/S. 4784, Department of Defense Appropriations Act for FY2027, provisions on defense technology.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Tax reform and tax policy.
NATIONAL EMPLOYMENT OPPORTUNITIES NETWORK via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Extension and improvements to federal employment tax credits. S. 492, Improve and Enhance the Work Opportunity Tax Credit Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CROWDSTRIKE, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to cybersecurity. H.R. 8800, National Defense Authorization Act, FY 2027, policies and proposals related to cybersecurity.
Filing targets: Defense, Dept of (DOD), Director of National Intelligence (ODNI), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · third_quarter · Q3
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
TTX COMPANY via DLA PIPER LLP (US)
2026 · third_quarter · RR
Policies and proposals related to truck size and weight issues; Surface Transportation Board reauthorization; polices and proposals related to the railroad industry.
STAX ENGINEERING, INC. via DLA PIPER LLP (US)
2026 · third_quarter · RR
S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision"
HADRON ENERGY, INC. via DLA PIPER LLP (US)
2026 · third_quarter · RR
Advocacy for design and development funding and federal adoption of micro modular nuclear reactor technology.
PIVOTAL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · RR
Independent dispute resolution under the No Surprises Act.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Medicare policies.
National security issues related to pharmaceutical industry, including supply chain.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
NOVARTIS via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Tariffs and biotechnology issues related to Treasury and competition with China.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Tax reform and tax policy.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Trade-related public policy around tariffs and intellectual property.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
MICHAELS STORES, INC. via DLA PIPER LLP (US)
2026 · second_quarter · RR
Policies and proposals related to tariff and trade issues.
Policies and proposals related to tariff and trade issues.
NATIONAL EMPLOYMENT OPPORTUNITIES NETWORK via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Extension and improvements to federal employment tax credits. S. 492, Improve and Enhance the Work Opportunity Tax Credit Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NAPATREE TECHNOLOGY, LLC via DLA PIPER LLP (US)
2026 · second_quarter · Q2
H.R. 9495/S. 4784, Department of Defense Appropriations Act for FY2027, provisions on defense technology.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to federal research funding. Federal student aid. S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Center for Tobacco products oversight. FDA oversight. H.R. 8646, Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
DSRB DEVELOPMENT GROUP via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Advocating for the creation of a financial institution to provide lending for increased spending in the defense industry and related infrastructure and technology.
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to university endowment tax.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTICULA GROUP INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policy issues related to tokenized assets. H.R. 3633, Digital Asset Market Clarity Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CROWDSTRIKE, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to cybersecurity.
Filing targets: Defense, Dept of (DOD), Director of National Intelligence (ODNI), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
ATLANTIC COAST CONFERENCE via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act. S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DSRB DEVELOPMENT GROUP via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Advocating for the creation of a financial institution to provide lending for increased spending in the defense industry and related infrastructure and technology.
ATLANTIC COAST CONFERENCE via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Tariffs.
Tax reform and tax policy.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Trade policies and agreements, including IP protections, and administrative tariff actions.
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to tax reform.
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to federal research funding. National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid.
Policies and proposals related to university endowment tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CROWDSTRIKE, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to cybersecurity.
Filing targets: Defense, Dept of (DOD), Director of National Intelligence (ODNI), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
ASSOCIATION OF AMERICAN UNIVERSITIES via DLA PIPER LLP (US)
2026 · first_quarter · 1T
Research security, research funding, and the importance of American research enterprise and higher education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Center for Tobacco products oversight. FDA oversight. Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2027, provisions on tobacco.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
PARTICULA GROUP INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policy issues related to tokenized assets. H.R. 3633, Digital Asset Market Clarity Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NAPATREE TECHNOLOGY, LLC via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Department of Defense Appropriations Act for FY2027, provisions on defense technology.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals impacting higher education for health sciences. Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to federal research funding. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTICULA GROUP INC. via DLA PIPER LLP (US)
2026 · first_quarter · RA
Policy issues related to tokenized assets.
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTICULA GROUP INC. via DLA PIPER LLP (US)
2026 · first_quarter · RR
Policy issues related to tokenized assets.
DSRB DEVELOPMENT GROUP via DLA PIPER LLP (US)
2025 · fourth_quarter · 4A
Advocating for the creation of a financial institution to provide lending for increased spending in the defense industry and related infrastructure and technology.
DSRB DEVELOPMENT GROUP via DLA PIPER LLP (US)
2025 · third_quarter · 3A
Advocating for the creation of a financial institution to provide lending for increased spending in the defense industry and related infrastructure and technology.
Filing targets: SENATE, State, Dept of (DOS), Treasury, Dept of
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
NOVARTIS via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Tax reform and tax policy.
Tariffs.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
ASSOCIATION OF AMERICAN UNIVERSITIES via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Research security, research funding, and the importance of American research enterprise and higher education. H.R. 5304/S. 2587, Departments of Labor/HHS/Education Appropriations Act, FY2026, provisions on federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Policies and proposals related to university endowment tax. Federal Student Aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DSRB DEVELOPMENT GROUP via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Advocating for the creation of a financial institution to provide lending for increased spending in the defense industry and related infrastructure and technology.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOGEN, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NAPATREE TECHNOLOGY, LLC via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on defense technology.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
LAZARUS AI via DLA PIPER LLP (US)
2025 · fourth_quarter · 4T
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Filing targets: Health & Human Services, Dept of (HHS), SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to federal research funding. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATLANTIC COAST CONFERENCE via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act.
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
REGENXBIO INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Issues related to rare disease.
Issues related to rare disease.
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Issues related to rare disease.
Issues related to rare disease.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · third_quarter · Q3
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Filing targets: Health & Human Services, Dept of (HHS), SENATE
ATLANTIC COAST CONFERENCE via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Legislative and regulatory proposals affecting intercollegiate athletics. H.R. 4312, SCORE Act. S. 2932, Student Athlete Fairness and Enforcement Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NAPATREE TECHNOLOGY, LLC via DLA PIPER LLP (US)
2025 · third_quarter · Q3
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on defense technology.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
DSRB DEVELOPMENT GROUP via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Advocating for the creation of a financial institution to provide lending for increased spending in the defense industry and related infrastructure and technology.
Filing targets: SENATE
NOVARTIS via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Tax reform and tax policy.
Tariffs.
UNITED WAY WORLDWIDE via DLA PIPER LLP (US)
2025 · third_quarter · RR
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
Policies and proposals related to disaster relief, housing, healthcare, and childcare.
COALITION FOR SMARTER REGULATION OF NICOTINE via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Center for Tobacco products oversight. FDA oversight. H.R. 4121/S. 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2026, provisions on tobacco.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSOCIATION OF AMERICAN UNIVERSITIES via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Research security, research funding, and the importance of American research enterprise and higher education. H.R. 5304/S. 2587, Departments of Labor/HHS/Education Appropriations Act, FY2026, provisions on federal research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LAZARUS AI via DLA PIPER LLP (US)
2025 · third_quarter · Q3
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act of FY2026, provisions regarding the DETERRENT Act.
Policies and proposals related to university endowment tax. H.R. 1, One Big Beautiful Bill Act, university endowment tax. Federal Student Aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Policies and proposals related to federal research funding. H.R. 1, One Big Beautiful Bill Act, federal student aid.
H.R. 1, One Big Beautiful Bill Act, university endowment tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Healthcare provisions in appropriations and budget legislation.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tax reform.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
National security issues related to pharmaceutical industry, including supply chain.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Trade-related public policy around tariffs and intellectual property.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tax reform.
Trade-related public policy around tariffs and intellectual property.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax reform.
Trade-related public policy around tariffs and intellectual property.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE